The Wegovy pill is oral semaglutide 25 mg, approved for weight reduction in December 2025 and sold as a once-daily tablet. This review reports what the trial registry and the label record about how it performs in people and what taking it involves. It gives no score and no verdict: whether it suits a particular person is a clinical question. Sources are dated below; the registry and label were read on 30 September 2026.
Prices are on Wegovy pill cost. How it compares with Lilly's pill is on Foundayo vs Wegovy pill. How a peptide survives being swallowed is on oral GLP-1s explained.
The result, as a distribution
Averages hide the question most people are asking — what are my chances? OASIS 4 (NCT05564117) randomised 307 adults with obesity, or overweight with a related condition, and without diabetes: 205 to the pill and 102 to placebo. Its posted results on ClinicalTrials.gov count how many reached each threshold at week 64, among those with a week-64 weight:
| Weight lost at week 64 | Oral semaglutide 25 mg (n = 192) | Placebo (n = 90) |
|---|---|---|
| At least 5% | 152 (79.2%) | 28 (31.1%) |
| At least 10% | 121 (63.0%) | 13 (14.4%) |
| At least 15% | 96 (50.0%) | 5 (5.6%) |
| At least 20% | 57 (29.7%) | 3 (3.3%) |
| Less than 5% | 40 (20.8%) | 62 (68.9%) |
Percentages computed by glp1ledger from the registry's posted counts.
Read the other way: about one in five people on the pill lost less than 5% — the threshold many insurers' renewal criteria use (see how insurers renew GLP-1 approvals). Half lost 15% or more.
The mean in the same posted analysis is −14.4% against −2.5%. The published trial reports −13.6% against −2.2% because it counts people whether or not they stayed on the tablet and imputes missing weights. Both are correct for what they measure; the lower one is closer to what happens to everyone who starts.
Of those randomised, 196 of 205 on the pill (95.6%) and 94 of 102 on placebo (92.2%) completed the trial. Completing the trial is not the same as staying on the tablet throughout; the registry's participant flow counts the former.
The daily rule — the part users actually talk about
The pill's label sets a routine the injection does not:
- once daily, in the morning, on an empty stomach;
- with water only, "up to 4 ounces" — no coffee, tea or juice;
- swallowed whole — "do not split, crush, chew or dissolve";
- then wait "at least 30 minutes" before eating, drinking anything else or taking other oral medicines;
- a missed tablet is skipped, and the next taken the following day.
The pharmacology section explains why. The tablet carries an absorption enhancer called SNAC, absorption happens mainly in the stomach, and only about 1% to 2% of the semaglutide is absorbed, against 89% from an injection. In the label's studies, absorption was higher with 50 mL of water than with 240 mL, and higher after a longer fast following the dose — the 30-minute wait is the tested compromise. The rules exist because small changes move the dose actually absorbed.
The tablet also changes other tablets: in the label's interaction study, levothyroxine exposure rose 33% when taken with oral semaglutide, and the label asks for monitoring of other oral medicines. Someone with a morning thyroid tablet has a timing question for the prescriber and pharmacist.
The variability warning
The label predicts that, in people without type 2 diabetes, average semaglutide levels on the 25 mg pill are comparable to the 2.4 mg weekly injection — but not equally spread. 90% of patients on the tablet had average levels between 27 and 186 nmol/L; on the injection, between 51 and 110. The pill's range spans about 6.9-fold, the shot's 2.2-fold.
Two further statements in the label bear on who the trial result applies to:
- The tablets "have not been studied for weight reduction in adults with type 2 diabetes."
- In people with type 2 diabetes, average levels on the pill were lower than on the injection, and "some patients with type 2 diabetes taking WEGOVY tablets may experience subtherapeutic semaglutide blood concentrations." The label's suggested response to an inadequate response is to consider alternatives, "including switching to WEGOVY injection."
OASIS 4 excluded diabetes, so its distribution above describes people without it.
Side effects in the trial
The posted adverse-event table over 71 weeks (204 on the pill, 102 on placebo):
| Event | Pill | Placebo |
|---|---|---|
| Nausea | 46.6% | 18.6% |
| Vomiting | 30.9% | 5.9% |
| Constipation | 20.1% | 9.8% |
| Dyspepsia | 18.1% | 8.8% |
| Diarrhoea | 17.6% | 8.8% |
| Belching (eructation) | 10.3% | 2.0% |
| Serious adverse events (any) | 8 people | 9 people |
The pattern is the class pattern — mostly gastrointestinal. The label's full record, including the boxed thyroid C-cell tumour warning and pancreatitis and gallbladder sections shared with the pen, is on Wegovy side effects.
The case against, stated plainly
- The routine is daily and unforgiving. A weekly injection takes seconds once a week; the pill asks for a fasted, water-only, 30-minute window every morning.
- One in five did not reach 5%. In OASIS 4, 20.8% of those with a week-64 weight lost less.
- Blood levels vary more. The label's own ranges show a wider spread than the injection, and a specific warning for people with type 2 diabetes, who were not studied for weight loss on the tablet.
- Nausea is common. Nearly half reported it in the trial, against under a fifth on placebo.
- The evidence is one weight-loss trial of 307 people. Lilly's Foundayo was tested in more people across its programme; there is no head-to-head between the two pills or between the pill and the pen.
What is not established
- How the pill compares with the injection in a randomised trial. None has been done for weight loss; the label's comparison is pharmacokinetic.
- Long-term outcomes beyond the trial. The label's cardiovascular risk-reduction indication for the tablets rests on the semaglutide programme; OASIS 4 itself ran 71 weeks.
- What happens after stopping the tablet specifically — the evidence on regain comes from the injection trials.
Price, in one line
Without insurance, $149 (1.5 mg), $199 (4 mg) and $299 (9 mg and 25 mg) per 30-tablet bottle, per Novo Nordisk's terms read on 30 September 2026 — worked through on Wegovy pill cost and against the other pill on GLP-1 pill cost. Where it sits among the other approved options is on best GLP-1 for weight loss; the tablet versus the older diabetes tablet is on Ozempic pill.
This review reports trial, registry and label data. It is not a recommendation to take or avoid the pill; that decision belongs with a prescriber who knows the person's history.
Sources
- ClinicalTrials.gov, NCT05564117 (OASIS 4), posted results: participant flow, outcome measures (percentage change in body weight; ≥5%, ≥10%, ≥15%, ≥20% responders) and adverse events; results first posted 2026-02-25; read via the ClinicalTrials.gov API v2 on 30 September 2026.
- Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med 2025;393(11):1077-1087. PubMed 40934115.
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk, DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18 — sections 2.1, 2.4, 8.6 and 12.3.